Leerink Partnrs Upgrades Voyager Therapeutics (NASDAQ:VYGR) to “Strong-Buy”

Voyager Therapeutics (NASDAQ:VYGR) was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating in a report issued on Wednesday, Zacks.com reports.

A number of other research firms also recently weighed in on VYGR. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, August 20th. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a research note on Wednesday. They set an “outperform” rating and a $15.00 price target on the stock. StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, October 11th. Finally, Wedbush lowered their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Voyager Therapeutics currently has a consensus rating of “Buy” and an average target price of $17.43.

Voyager Therapeutics Stock Up 15.5 %

NASDAQ VYGR opened at $7.91 on Wednesday. The firm has a market cap of $430.26 million, a P/E ratio of -158.20 and a beta of 0.91. Voyager Therapeutics has a 52-week low of $5.71 and a 52-week high of $11.72. The business’s 50-day moving average price is $6.48 and its 200 day moving average price is $7.73.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. The firm had revenue of $29.58 million during the quarter, compared to the consensus estimate of $11.52 million. During the same quarter last year, the firm earned ($0.51) earnings per share. As a group, analysts anticipate that Voyager Therapeutics will post -1.44 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the transaction, the insider now owns 86,001 shares of the company’s stock, valued at $500,525.82. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.53% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its stake in Voyager Therapeutics by 2.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock valued at $925,000 after purchasing an additional 2,030 shares in the last quarter. Commonwealth Equity Services LLC acquired a new stake in shares of Voyager Therapeutics during the first quarter worth approximately $530,000. BNP Paribas Financial Markets increased its stake in shares of Voyager Therapeutics by 198.6% in the first quarter. BNP Paribas Financial Markets now owns 48,769 shares of the company’s stock worth $454,000 after buying an additional 32,437 shares during the last quarter. Empowered Funds LLC raised its holdings in Voyager Therapeutics by 8.2% in the first quarter. Empowered Funds LLC now owns 39,471 shares of the company’s stock valued at $367,000 after acquiring an additional 2,975 shares in the last quarter. Finally, ClariVest Asset Management LLC boosted its stake in Voyager Therapeutics by 59.3% during the 1st quarter. ClariVest Asset Management LLC now owns 100,123 shares of the company’s stock valued at $932,000 after acquiring an additional 37,275 shares during the last quarter. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.